Pharma & Healthcare

Global C-MET and HGF Inhibitors Market Research Report 2025

The global market for C-MET and HGF Inhibitors was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for C-MET and HGF Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for C-MET and HGF Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of C-MET and HGF Inhibitors include Exelixis, lpsen, Pfizer, Novartis, Takeda, Merck, Daiichi Sankyo, GSK, Bristol-Myers Squibb, Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for C-MET and HGF Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET and HGF Inhibitors.
The C-MET and HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global C-MET and HGF Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the C-MET and HGF Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Exelixis
lpsen
Pfizer
Novartis
Takeda
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb
Roche
AVEO Pharmaceuticals
Amgen
Astra Zeneca
Mirati Therapeutics
Eli Lilly
Eisai
Johnson & Johnson
Hutchison MediPharma
Kringle Pharmaceuticals
Segment by Type
Cabozantinib
Crizotinib
Others
Segment by Application
Clinic
Hospital
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of C-MET and HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of C-MET and HGF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report. 
1 C-MET and HGF Inhibitors Market Overview
1.1 Product Definition
1.2 C-MET and HGF Inhibitors by Type
1.2.1 Global C-MET and HGF Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cabozantinib
1.2.3 Crizotinib
1.2.4 Others
1.3 C-MET and HGF Inhibitors by Application
1.3.1 Global C-MET and HGF Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global C-MET and HGF Inhibitors Market Size Estimates and Forecasts
1.4.1 Global C-MET and HGF Inhibitors Revenue 2020-2031
1.4.2 Global C-MET and HGF Inhibitors Sales 2020-2031
1.4.3 Global C-MET and HGF Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 C-MET and HGF Inhibitors Market Competition by Manufacturers
2.1 Global C-MET and HGF Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global C-MET and HGF Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global C-MET and HGF Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of C-MET and HGF Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of C-MET and HGF Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of C-MET and HGF Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of C-MET and HGF Inhibitors, Date of Enter into This Industry
2.8 Global C-MET and HGF Inhibitors Market Competitive Situation and Trends
2.8.1 Global C-MET and HGF Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest C-MET and HGF Inhibitors Players Market Share by Revenue
2.8.3 Global C-MET and HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global C-MET and HGF Inhibitors Market Scenario by Region
3.1 Global C-MET and HGF Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global C-MET and HGF Inhibitors Sales by Region: 2020-2031
3.2.1 Global C-MET and HGF Inhibitors Sales by Region: 2020-2025
3.2.2 Global C-MET and HGF Inhibitors Sales by Region: 2026-2031
3.3 Global C-MET and HGF Inhibitors Revenue by Region: 2020-2031
3.3.1 Global C-MET and HGF Inhibitors Revenue by Region: 2020-2025
3.3.2 Global C-MET and HGF Inhibitors Revenue by Region: 2026-2031
3.4 North America C-MET and HGF Inhibitors Market Facts & Figures by Country
3.4.1 North America C-MET and HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America C-MET and HGF Inhibitors Sales by Country (2020-2031)
3.4.3 North America C-MET and HGF Inhibitors Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe C-MET and HGF Inhibitors Market Facts & Figures by Country
3.5.1 Europe C-MET and HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe C-MET and HGF Inhibitors Sales by Country (2020-2031)
3.5.3 Europe C-MET and HGF Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific C-MET and HGF Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific C-MET and HGF Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific C-MET and HGF Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific C-MET and HGF Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America C-MET and HGF Inhibitors Market Facts & Figures by Country
3.7.1 Latin America C-MET and HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America C-MET and HGF Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America C-MET and HGF Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa C-MET and HGF Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa C-MET and HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa C-MET and HGF Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa C-MET and HGF Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global C-MET and HGF Inhibitors Sales by Type (2020-2031)
4.1.1 Global C-MET and HGF Inhibitors Sales by Type (2020-2025)
4.1.2 Global C-MET and HGF Inhibitors Sales by Type (2026-2031)
4.1.3 Global C-MET and HGF Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global C-MET and HGF Inhibitors Revenue by Type (2020-2031)
4.2.1 Global C-MET and HGF Inhibitors Revenue by Type (2020-2025)
4.2.2 Global C-MET and HGF Inhibitors Revenue by Type (2026-2031)
4.2.3 Global C-MET and HGF Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global C-MET and HGF Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global C-MET and HGF Inhibitors Sales by Application (2020-2031)
5.1.1 Global C-MET and HGF Inhibitors Sales by Application (2020-2025)
5.1.2 Global C-MET and HGF Inhibitors Sales by Application (2026-2031)
5.1.3 Global C-MET and HGF Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global C-MET and HGF Inhibitors Revenue by Application (2020-2031)
5.2.1 Global C-MET and HGF Inhibitors Revenue by Application (2020-2025)
5.2.2 Global C-MET and HGF Inhibitors Revenue by Application (2026-2031)
5.2.3 Global C-MET and HGF Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global C-MET and HGF Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Exelixis
6.1.1 Exelixis Company Information
6.1.2 Exelixis Description and Business Overview
6.1.3 Exelixis C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Exelixis C-MET and HGF Inhibitors Product Portfolio
6.1.5 Exelixis Recent Developments/Updates
6.2 lpsen
6.2.1 lpsen Company Information
6.2.2 lpsen Description and Business Overview
6.2.3 lpsen C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 lpsen C-MET and HGF Inhibitors Product Portfolio
6.2.5 lpsen Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer C-MET and HGF Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis C-MET and HGF Inhibitors Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Company Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Takeda C-MET and HGF Inhibitors Product Portfolio
6.5.5 Takeda Recent Developments/Updates
6.6 Merck
6.6.1 Merck Company Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Merck C-MET and HGF Inhibitors Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 Daiichi Sankyo
6.7.1 Daiichi Sankyo Company Information
6.7.2 Daiichi Sankyo Description and Business Overview
6.7.3 Daiichi Sankyo C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Daiichi Sankyo C-MET and HGF Inhibitors Product Portfolio
6.7.5 Daiichi Sankyo Recent Developments/Updates
6.8 GSK
6.8.1 GSK Company Information
6.8.2 GSK Description and Business Overview
6.8.3 GSK C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 GSK C-MET and HGF Inhibitors Product Portfolio
6.8.5 GSK Recent Developments/Updates
6.9 Bristol-Myers Squibb
6.9.1 Bristol-Myers Squibb Company Information
6.9.2 Bristol-Myers Squibb Description and Business Overview
6.9.3 Bristol-Myers Squibb C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Bristol-Myers Squibb C-MET and HGF Inhibitors Product Portfolio
6.9.5 Bristol-Myers Squibb Recent Developments/Updates
6.10 Roche
6.10.1 Roche Company Information
6.10.2 Roche Description and Business Overview
6.10.3 Roche C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Roche C-MET and HGF Inhibitors Product Portfolio
6.10.5 Roche Recent Developments/Updates
6.11 AVEO Pharmaceuticals
6.11.1 AVEO Pharmaceuticals Company Information
6.11.2 AVEO Pharmaceuticals Description and Business Overview
6.11.3 AVEO Pharmaceuticals C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 AVEO Pharmaceuticals C-MET and HGF Inhibitors Product Portfolio
6.11.5 AVEO Pharmaceuticals Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Company Information
6.12.2 Amgen Description and Business Overview
6.12.3 Amgen C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Amgen C-MET and HGF Inhibitors Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Astra Zeneca
6.13.1 Astra Zeneca Company Information
6.13.2 Astra Zeneca Description and Business Overview
6.13.3 Astra Zeneca C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Astra Zeneca C-MET and HGF Inhibitors Product Portfolio
6.13.5 Astra Zeneca Recent Developments/Updates
6.14 Mirati Therapeutics
6.14.1 Mirati Therapeutics Company Information
6.14.2 Mirati Therapeutics Description and Business Overview
6.14.3 Mirati Therapeutics C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Mirati Therapeutics C-MET and HGF Inhibitors Product Portfolio
6.14.5 Mirati Therapeutics Recent Developments/Updates
6.15 Eli Lilly
6.15.1 Eli Lilly Company Information
6.15.2 Eli Lilly Description and Business Overview
6.15.3 Eli Lilly C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Eli Lilly C-MET and HGF Inhibitors Product Portfolio
6.15.5 Eli Lilly Recent Developments/Updates
6.16 Eisai
6.16.1 Eisai Company Information
6.16.2 Eisai Description and Business Overview
6.16.3 Eisai C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Eisai C-MET and HGF Inhibitors Product Portfolio
6.16.5 Eisai Recent Developments/Updates
6.17 Johnson & Johnson
6.17.1 Johnson & Johnson Company Information
6.17.2 Johnson & Johnson Description and Business Overview
6.17.3 Johnson & Johnson C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Johnson & Johnson C-MET and HGF Inhibitors Product Portfolio
6.17.5 Johnson & Johnson Recent Developments/Updates
6.18 Hutchison MediPharma
6.18.1 Hutchison MediPharma Company Information
6.18.2 Hutchison MediPharma Description and Business Overview
6.18.3 Hutchison MediPharma C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Hutchison MediPharma C-MET and HGF Inhibitors Product Portfolio
6.18.5 Hutchison MediPharma Recent Developments/Updates
6.19 Kringle Pharmaceuticals
6.19.1 Kringle Pharmaceuticals Company Information
6.19.2 Kringle Pharmaceuticals Description and Business Overview
6.19.3 Kringle Pharmaceuticals C-MET and HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Kringle Pharmaceuticals C-MET and HGF Inhibitors Product Portfolio
6.19.5 Kringle Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 C-MET and HGF Inhibitors Industry Chain Analysis
7.2 C-MET and HGF Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 C-MET and HGF Inhibitors Production Mode & Process Analysis
7.4 C-MET and HGF Inhibitors Sales and Marketing
7.4.1 C-MET and HGF Inhibitors Sales Channels
7.4.2 C-MET and HGF Inhibitors Distributors
7.5 C-MET and HGF Inhibitors Customer Analysis
8 C-MET and HGF Inhibitors Market Dynamics
8.1 C-MET and HGF Inhibitors Industry Trends
8.2 C-MET and HGF Inhibitors Market Drivers
8.3 C-MET and HGF Inhibitors Market Challenges
8.4 C-MET and HGF Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global C-MET and HGF Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global C-MET and HGF Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global C-MET and HGF Inhibitors Market Competitive Situation by Manufacturers in 2024
Table 4. Global C-MET and HGF Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global C-MET and HGF Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 6. Global C-MET and HGF Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global C-MET and HGF Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market C-MET and HGF Inhibitors Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of C-MET and HGF Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of C-MET and HGF Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of C-MET and HGF Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of C-MET and HGF Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global C-MET and HGF Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET and HGF Inhibitors as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global C-MET and HGF Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global C-MET and HGF Inhibitors Sales by Region (2020-2025) & (K Units)
Table 18. Global C-MET and HGF Inhibitors Sales Market Share by Region (2020-2025)
Table 19. Global C-MET and HGF Inhibitors Sales by Region (2026-2031) & (K Units)
Table 20. Global C-MET and HGF Inhibitors Sales Market Share by Region (2026-2031)
Table 21. Global C-MET and HGF Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global C-MET and HGF Inhibitors Revenue Market Share by Region (2020-2025)
Table 23. Global C-MET and HGF Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global C-MET and HGF Inhibitors Revenue Market Share by Region (2026-2031)
Table 25. North America C-MET and HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America C-MET and HGF Inhibitors Sales by Country (2020-2025) & (K Units)
Table 27. North America C-MET and HGF Inhibitors Sales by Country (2026-2031) & (K Units)
Table 28. North America C-MET and HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America C-MET and HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe C-MET and HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe C-MET and HGF Inhibitors Sales by Country (2020-2025) & (K Units)
Table 32. Europe C-MET and HGF Inhibitors Sales by Country (2026-2031) & (K Units)
Table 33. Europe C-MET and HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe C-MET and HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific C-MET and HGF Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific C-MET and HGF Inhibitors Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific C-MET and HGF Inhibitors Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific C-MET and HGF Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific C-MET and HGF Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America C-MET and HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America C-MET and HGF Inhibitors Sales by Country (2020-2025) & (K Units)
Table 42. Latin America C-MET and HGF Inhibitors Sales by Country (2026-2031) & (K Units)
Table 43. Latin America C-MET and HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America C-MET and HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa C-MET and HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa C-MET and HGF Inhibitors Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa C-MET and HGF Inhibitors Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa C-MET and HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa C-MET and HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global C-MET and HGF Inhibitors Sales (K Units) by Type (2020-2025)
Table 51. Global C-MET and HGF Inhibitors Sales (K Units) by Type (2026-2031)
Table 52. Global C-MET and HGF Inhibitors Sales Market Share by Type (2020-2025)
Table 53. Global C-MET and HGF Inhibitors Sales Market Share by Type (2026-2031)
Table 54. Global C-MET and HGF Inhibitors Revenue (US$ Million) by Type (2020-2025)
Table 55. Global C-MET and HGF Inhibitors Revenue (US$ Million) by Type (2026-2031)
Table 56. Global C-MET and HGF Inhibitors Revenue Market Share by Type (2020-2025)
Table 57. Global C-MET and HGF Inhibitors Revenue Market Share by Type (2026-2031)
Table 58. Global C-MET and HGF Inhibitors Price (US$/Unit) by Type (2020-2025)
Table 59. Global C-MET and HGF Inhibitors Price (US$/Unit) by Type (2026-2031)
Table 60. Global C-MET and HGF Inhibitors Sales (K Units) by Application (2020-2025)
Table 61. Global C-MET and HGF Inhibitors Sales (K Units) by Application (2026-2031)
Table 62. Global C-MET and HGF Inhibitors Sales Market Share by Application (2020-2025)
Table 63. Global C-MET and HGF Inhibitors Sales Market Share by Application (2026-2031)
Table 64. Global C-MET and HGF Inhibitors Revenue (US$ Million) by Application (2020-2025)
Table 65. Global C-MET and HGF Inhibitors Revenue (US$ Million) by Application (2026-2031)
Table 66. Global C-MET and HGF Inhibitors Revenue Market Share by Application (2020-2025)
Table 67. Global C-MET and HGF Inhibitors Revenue Market Share by Application (2026-2031)
Table 68. Global C-MET and HGF Inhibitors Price (US$/Unit) by Application (2020-2025)
Table 69. Global C-MET and HGF Inhibitors Price (US$/Unit) by Application (2026-2031)
Table 70. Exelixis Company Information
Table 71. Exelixis Description and Business Overview
Table 72. Exelixis C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Exelixis C-MET and HGF Inhibitors Product
Table 74. Exelixis Recent Developments/Updates
Table 75. lpsen Company Information
Table 76. lpsen Description and Business Overview
Table 77. lpsen C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. lpsen C-MET and HGF Inhibitors Product
Table 79. lpsen Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Pfizer C-MET and HGF Inhibitors Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Novartis Company Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Novartis C-MET and HGF Inhibitors Product
Table 89. Novartis Recent Developments/Updates
Table 90. Takeda Company Information
Table 91. Takeda Description and Business Overview
Table 92. Takeda C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Takeda C-MET and HGF Inhibitors Product
Table 94. Takeda Recent Developments/Updates
Table 95. Merck Company Information
Table 96. Merck Description and Business Overview
Table 97. Merck C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Merck C-MET and HGF Inhibitors Product
Table 99. Merck Recent Developments/Updates
Table 100. Daiichi Sankyo Company Information
Table 101. Daiichi Sankyo Description and Business Overview
Table 102. Daiichi Sankyo C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Daiichi Sankyo C-MET and HGF Inhibitors Product
Table 104. Daiichi Sankyo Recent Developments/Updates
Table 105. GSK Company Information
Table 106. GSK Description and Business Overview
Table 107. GSK C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. GSK C-MET and HGF Inhibitors Product
Table 109. GSK Recent Developments/Updates
Table 110. Bristol-Myers Squibb Company Information
Table 111. Bristol-Myers Squibb Description and Business Overview
Table 112. Bristol-Myers Squibb C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Bristol-Myers Squibb C-MET and HGF Inhibitors Product
Table 114. Bristol-Myers Squibb Recent Developments/Updates
Table 115. Roche Company Information
Table 116. Roche Description and Business Overview
Table 117. Roche C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Roche C-MET and HGF Inhibitors Product
Table 119. Roche Recent Developments/Updates
Table 120. AVEO Pharmaceuticals Company Information
Table 121. AVEO Pharmaceuticals Description and Business Overview
Table 122. AVEO Pharmaceuticals C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. AVEO Pharmaceuticals C-MET and HGF Inhibitors Product
Table 124. AVEO Pharmaceuticals Recent Developments/Updates
Table 125. Amgen Company Information
Table 126. Amgen Description and Business Overview
Table 127. Amgen C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Amgen C-MET and HGF Inhibitors Product
Table 129. Amgen Recent Developments/Updates
Table 130. Astra Zeneca Company Information
Table 131. Astra Zeneca Description and Business Overview
Table 132. Astra Zeneca C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Astra Zeneca C-MET and HGF Inhibitors Product
Table 134. Astra Zeneca Recent Developments/Updates
Table 135. Mirati Therapeutics Company Information
Table 136. Mirati Therapeutics Description and Business Overview
Table 137. Mirati Therapeutics C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Mirati Therapeutics C-MET and HGF Inhibitors Product
Table 139. Mirati Therapeutics Recent Developments/Updates
Table 140. Eli Lilly Company Information
Table 141. Eli Lilly Description and Business Overview
Table 142. Eli Lilly C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Eli Lilly C-MET and HGF Inhibitors Product
Table 144. Eli Lilly Recent Developments/Updates
Table 145. Eisai Company Information
Table 146. Eisai Description and Business Overview
Table 147. Eisai C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Eisai C-MET and HGF Inhibitors Product
Table 149. Eisai Recent Developments/Updates
Table 150. Johnson & Johnson Company Information
Table 151. Johnson & Johnson Description and Business Overview
Table 152. Johnson & Johnson C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Johnson & Johnson C-MET and HGF Inhibitors Product
Table 154. Johnson & Johnson Recent Developments/Updates
Table 155. Hutchison MediPharma Company Information
Table 156. Hutchison MediPharma Description and Business Overview
Table 157. Hutchison MediPharma C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Hutchison MediPharma C-MET and HGF Inhibitors Product
Table 159. Hutchison MediPharma Recent Developments/Updates
Table 160. Kringle Pharmaceuticals Company Information
Table 161. Kringle Pharmaceuticals Description and Business Overview
Table 162. Kringle Pharmaceuticals C-MET and HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Kringle Pharmaceuticals C-MET and HGF Inhibitors Product
Table 164. Kringle Pharmaceuticals Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. C-MET and HGF Inhibitors Distributors List
Table 168. C-MET and HGF Inhibitors Customers List
Table 169. C-MET and HGF Inhibitors Market Trends
Table 170. C-MET and HGF Inhibitors Market Drivers
Table 171. C-MET and HGF Inhibitors Market Challenges
Table 172. C-MET and HGF Inhibitors Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
Table 176. Authors List of This Report


List of Figures
Figure 1. Product Picture of C-MET and HGF Inhibitors
Figure 2. Global C-MET and HGF Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global C-MET and HGF Inhibitors Market Share by Type: 2024 & 2031
Figure 4. Cabozantinib Product Picture
Figure 5. Crizotinib Product Picture
Figure 6. Others Product Picture
Figure 7. Global C-MET and HGF Inhibitors Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global C-MET and HGF Inhibitors Market Share by Application: 2024 & 2031
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Global C-MET and HGF Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global C-MET and HGF Inhibitors Market Size (2020-2031) & (US$ Million)
Figure 14. Global C-MET and HGF Inhibitors Sales (2020-2031) & (K Units)
Figure 15. Global C-MET and HGF Inhibitors Average Price (US$/Unit) & (2020-2031)
Figure 16. C-MET and HGF Inhibitors Report Years Considered
Figure 17. C-MET and HGF Inhibitors Sales Share by Manufacturers in 2024
Figure 18. Global C-MET and HGF Inhibitors Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest C-MET and HGF Inhibitors Players: Market Share by Revenue in C-MET and HGF Inhibitors in 2024
Figure 20. C-MET and HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global C-MET and HGF Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America C-MET and HGF Inhibitors Sales Market Share by Country (2020-2031)
Figure 23. North America C-MET and HGF Inhibitors Revenue Market Share by Country (2020-2031)
Figure 24. United States C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe C-MET and HGF Inhibitors Sales Market Share by Country (2020-2031)
Figure 27. Europe C-MET and HGF Inhibitors Revenue Market Share by Country (2020-2031)
Figure 28. Germany C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific C-MET and HGF Inhibitors Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific C-MET and HGF Inhibitors Revenue Market Share by Region (2020-2031)
Figure 35. China C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America C-MET and HGF Inhibitors Sales Market Share by Country (2020-2031)
Figure 43. Latin America C-MET and HGF Inhibitors Revenue Market Share by Country (2020-2031)
Figure 44. Mexico C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa C-MET and HGF Inhibitors Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa C-MET and HGF Inhibitors Revenue Market Share by Country (2020-2031)
Figure 49. Turkey C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE C-MET and HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of C-MET and HGF Inhibitors by Type (2020-2031)
Figure 53. Global Revenue Market Share of C-MET and HGF Inhibitors by Type (2020-2031)
Figure 54. Global C-MET and HGF Inhibitors Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of C-MET and HGF Inhibitors by Application (2020-2031)
Figure 56. Global Revenue Market Share of C-MET and HGF Inhibitors by Application (2020-2031)
Figure 57. Global C-MET and HGF Inhibitors Price (US$/Unit) by Application (2020-2031)
Figure 58. C-MET and HGF Inhibitors Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies